2026-05-08T19:57:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/200542024-09-27T08:43:43Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Gonzalez-Lopez, Esther author McPhail, Ellen D author Salas-Anton, Clara author Dominguez, Fernando author Gertz, Morie A author Dispenzieri, Angela author Dasari, Surendra author Milani, Paolo author Verga, Laura author Grogan, Martha author Palladini, Giovanni author Garcia-Pavia, Pablo author 2024-03-19 Cardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly effective specific therapies have recently become available for the 2 most frequent forms of cardiac amyloidosis: immunoglobulin light chain amyloidosis and transthyretin (ATTR) amyloidosis. Nevertheless, initiation of specific therapies requires recognition of cardiac amyloidosis and appropriate characterization of the amyloid type. Although noninvasive diagnosis is possible for ATTR cardiac amyloidosis, histological demonstration and typing of amyloid deposits is still required for a substantial number of patients with ATTR and in all patients with light chain amyloidosis and other rarer forms of cardiac amyloidosis. Amyloid histological typing can be performed using different techniques: mass spectrometry, immunohistochemistry, and immunoelectron microscopy. This review describes which patients require histological confirmation of cardiac amyloidosis along with when and how to type amyloid deposits in histologic specimens. Furthermore, it covers the characteristics and limitations of the different typing methods that are available in clinical practice. J Am Coll Cardiol. 2024 Mar 19;83(11):1085-1099. 10.1016/j.jacc.2024.01.010 1558-3597 Journal of the American College of Cardiology 38479957 http://hdl.handle.net/20.500.12105/20054 Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.